VKTX - Viking Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.60
-0.17 (-1.94%)
At close: 4:00PM EST

8.60 0.00 (0.00%)
Pre-Market: 7:25AM EST

Stock chart is not supported by your current browser
Previous Close8.77
Open8.71
Bid8.58 x 3000
Ask8.70 x 900
Day's Range8.57 - 8.78
52 Week Range3.69 - 24.00
Volume4,519
Avg. Volume2,854,832
Market Cap614.555M
Beta (3Y Monthly)3.15
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.79
Trade prices are not sourced from all markets
  • ACCESSWIREyesterday

    Healthcare Companies Investors are Watching

    HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you ...

  • ACCESSWIRE3 days ago

    4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)

    CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.

  • 3 Top Biotech Stocks to Buy in February
    Motley Fool5 days ago

    3 Top Biotech Stocks to Buy in February

    Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.

  • Should You Buy Viking Therapeutics After Gilead Drug Failure?
    InvestorPlace8 days ago

    Should You Buy Viking Therapeutics After Gilead Drug Failure?

    Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its Phase 3 clinical trial. This gave a possible opening to Viking Therapeutics, which gave a boost to VKTX stock.Source: Shutterstock Does that make it a buy? Let's examine the stock a bit more closely. If you haven't heard of VKTX stock before, don't feel guilty. With a market cap of just $650 million, it's not a well-known company. It's not a Bristol-Myers Squibb (NYSE:BMY), Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB) or another large cap biotech company. Breaking Down VKTX StockViking Therapeutics is a self-described "clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders." The company is working on several treatments, one of which includes enrolling VK2809, which is aimed at fatty liver and hypercholesterolemia, in a Phase 2 study. Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week, thus giving some hope to VKTX stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The company also has VK5211, "an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation."At the end of the day, Viking Therapeutics has some intriguing developments in its pipeline. But at the same time, this is also a speculative biotech company. Investors are, to some degree, betting on a binary event. Either VKTX stock is a multi-bagger with big-time potential if it gains regulatory approval and/or is acquired by a larger company, or neither of those things happen and it's a total dud. That's the nature of the beast with young biotech stocks.Case in point? Viking Therapeutics stock doesn't have any revenue. Its pipeline is promising, but that's all investors are betting on at this point. There's no real way to evaluate the business because there is no business! At least in the traditional sense. VKTX has enough money in the bank to fund its operations for the time being, but its future hinges solely on its treatments. Trading VKTX StockHopefully the chart above doesn't seem too complex. I only wanted to lay out a few different levels and prior trends that played a role in VKTX stock over the last 12 months.Like most of the market, VKTX came into Q4 near its highs, although admittedly under some pressure already. Still, the stock was pummeled along with the S&P 500 and other major market indices as Q4 got under way. VKTX stock price bottomed near $7 on Christmas Eve and has been working higher since.VKTX stock is now over the 50-day and 21-day moving averages. For traders and investors that are going in on this, perhaps consider using a $7 as a key reference level. Below this mark and Viking Therapeutics stock could be in trouble.As much as I want to say that the stock is okay over uptrend support (purple line) and moving average support -- and really, it is -- know that this is a speculative position that is subject to extreme moves in both directions. These moves can appear overnight and there's little investors can do about it other than planning ahead with proper position sizing. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? For those that don't want such a speculative position, consider choosing between two companies like Celgene and Gilead.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Should You Buy Viking Therapeutics After Gilead Drug Failure? appeared first on InvestorPlace.

  • Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
    Zacks10 days ago

    Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

    Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

  • Here's Why Viking Therapeutics Rose as Much as 13.9% Today
    Motley Fool10 days ago

    Here's Why Viking Therapeutics Rose as Much as 13.9% Today

    A rival's setback is this small cap's gain, right?

  • ACCESSWIRE10 days ago

    These Healthcare Stocks Could Surpass Investor Expectations

    Companies working in the healthcare sector are tasked with meeting the growing demand for effective treatment options given that, almost every day, medical experts discover a new disease or ailment. Premier Health Group (OTC:PHGRF) (CSE:PHGI), CAS Medical Systems Inc (CASM), CorMedix Inc (NYSE American: CRMD), and Viking Therapeutics Inc (VKTX) represent four healthcare companies determined to create products to help consumers have a better life.

  • Viking Therapeutics Breaks Out After Gilead's Clinical Failure
    Investopedia10 days ago

    Viking Therapeutics Breaks Out After Gilead's Clinical Failure

    Viking Therapeutics shares moved higher after an analyst suggested that it could become a takeover target for Gilead following a clinical failure.

  • Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript
    Motley Fool14 days ago

    Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending December 31, 2018.

  • Zacks Small Cap Researchlast month

    VKTX: No Cardio Toxicity Concerns for VK2809

    VK2809 is an agonist of the thyroid hormone receptor beta (TRβ). There are two major isoforms of the thyroid hormone receptor (TR), TRα and TRβ, which have markedly different expression patterns. TRα expression is highest in the heart and brain while TRβ expression is highest in the liver (Bookout et al., 2006).

  • Viking Therapeutics Stock Regains Ground
    Investopedialast month

    Viking Therapeutics Stock Regains Ground

    Viking Therapeutics fell earlier this week after Citron Research released a bearish report on licensor Ligand Pharma, but shares recovered on Thursday.

  • Citron Says Ligand Has 80% Downside in Explosive Note
    Investopedialast month

    Citron Says Ligand Has 80% Downside in Explosive Note

    Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.

  • Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It
    Investor's Business Dailylast month

    Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It

    Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."

  • Benzingalast month

    Ligand Pharmaceuticals Hit By Bearish Citron Report

    Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) shares were falling Wednesday after Citron Research issued a report alleging that Ligand’s business model is a “pipe dream," saying the company is deceiving ...

  • 3 Great Stocks Under $10
    Motley Foollast month

    3 Great Stocks Under $10

    It's not the low share price that makes these stocks attractive, it's their huge growth prospects.

  • 3 Top Biotech Stocks to Buy in January
    Motley Foollast month

    3 Top Biotech Stocks to Buy in January

    Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.

  • NASH Space in Focus in 2019 as Firms Look to Diversify
    Zackslast month

    NASH Space in Focus in 2019 as Firms Look to Diversify

    NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

  • Here's Why Viking Therapeutics Slid 32.2% in December
    Motley Foollast month

    Here's Why Viking Therapeutics Slid 32.2% in December

    A market scorned for clinical-stage biotech stocks tore a big chunk from this NASH drug developer.

  • Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018
    Motley Foollast month

    Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018

    The clinical-stage biotech hopes to tap into what could be a megablockbuster indication.

  • ACCESSWIRE2 months ago

    Biotech Stocks Set to Start 2019 Off with a Bang

    HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a ...

  • PR Newswire2 months ago

    Viking Therapeutics to Present at Biotech Showcase 2019

    SAN DIEGO , Jan. 2, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

  • 3 Top Small-Cap Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Small-Cap Stocks to Buy Right Now

    These scrawny stocks are bargains that should have investors licking their lips.

  • Why Viking Therapeutics Sank Today
    Motley Fool2 months ago

    Why Viking Therapeutics Sank Today

    A market sell-off caused the clinical-stage biotech stock to fall hard.

  • 3 Biotech Stocks That Are Too Cheap to Ignore
    Motley Fool2 months ago

    3 Biotech Stocks That Are Too Cheap to Ignore

    These three biotech stocks could prove to be outstanding bargains for long-term investors.

  • Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics
    Motley Fool2 months ago

    Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics

    Both of these NASH stocks have what it takes to overcome a bear market, but which is the better pick now?